Saturday 11 April 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Researchers discover link between gene and cause of blindness

Researchers discover link between gene and cause of blindness

17 November 2008

Macular degeneration is one of the leading causes of blindness in people over the age of 60 and a trans-Atlantic study may have found the culprit behind this problem. Researchers from the University of Southampton in the UK and the University of Iowa in the USA believe the Serping 1 gene is responsible for age-related macular degeneration (AMD). This discovery is expected to help scientists find better treatments and improve screening processes for patients. The finding was recently published in the on-line version of The Lancet.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

BioNTech and DualityBio’s ADC success
Biotechnology
BioNTech and DualityBio’s ADC success
11 April 2026
Pharmaceutical
MHRA approves Tryngolza for FCS
11 April 2026
Pharmaceutical
Boehringer hands CT-155 rights to Click in schizophrenia pivot
10 April 2026
Biotechnology
Daiichi taps Imagene to sharpen cancer biomarker discovery
10 April 2026
Pharmaceutical
Annovis secures financing for buntanetap’s NDA submission
10 April 2026
Pharmaceutical
Tempus AI expands collaboration with Gilead
10 April 2026
Pharmaceutical
Medicines Australia firmly opposes US tariffs on pharmaceuticals
10 April 2026


Company Spotlight

Fate Therapeutics
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze